New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
09:19 EDTAGN, VRXValeant's raised Allergan bid may not be enough, says Wells Fargo
Wells Fargo believes Valeant's (VRX) new offer for Allergan (AGN), which includes $10 more per share in cash and a $25 per share contingent value right for DARPin, may still be insufficient for Allergan. Wells notes that based on Valeant's last closing price, the total new offer for Allergan is around $166 per share. Shares of Allergan are down $1.03 to $163.99 in pre-market trading while Valeant shares are down 99c to $128.96.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use